Shiyao Group: SYH2066 tablets approved for clinical trials in China.

The Board of Directors of the Shiyao Group is pleased to announce that the SYH2066 tablet developed by the group has been approved by the National Medical Products Administration of the People's Republic of China in September 2025 for clinical trials in China. This product is a chemically class 1 new drug independently developed by the group, which is a new oral small molecule candidate drug that acts on respiratory syncytial virus. The approved indication for this application is for the treatment of respiratory infections caused by RSV. Preclinical studies have shown that the product has good oral bioavailability and other pharmacokinetic properties, can significantly reduce RSV virus titers in disease animal models, and has high safety. Currently, there are no small molecule drugs on the market targeting RSV domestically and internationally. This product is expected to be an effective treatment for this disease and has high clinical development value.